09/18/2025
📣Three Thing Thursday📣
It's day 4 of National Eczema Awareness week!
M24-601 is a total of 32-weeks. This study will compare two medications, Renvoq and Dupixent. This study will consist of 2 periods: Period 1 is an 8-week open-label treatment period to determine your randomization to either Renvoq or Dupixent. Period 2 is a 24-week open-label treatment period for those who completed period 1. At week 12, patients will be reassigned medication doses based off their Eczema Area Severity Index Score (EASI). If you qualify for the study, all of the care you will receive will be at no cost to you and you will be reimbursed for your time with each completed visit!
If your looking for a new treatment to help your stubborn moderate to severe Eczema, give us a call today and schedule a screening!